122 related articles for article (PubMed ID: 8782131)
1. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients.
Wise CM; Vuyyuru S; Roberts WN
J Rheumatol; 1996 Jun; 23(6):1005-10. PubMed ID: 8782131
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus.
Ravelli A; Ballardini G; Viola S; Villa I; Ruperto N; Martini A
J Rheumatol; 1998 Mar; 25(3):572-5. PubMed ID: 9517783
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis.
Rahman P; Humphrey-Murto S; Gladman DD; Urowitz MB
J Rheumatol; 1998 Feb; 25(2):243-6. PubMed ID: 9489814
[TBL] [Abstract][Full Text] [Related]
4. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
Carneiro JR; Sato EI
J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate in systemic lupus erythematosus.
Walz LeBlanc BA; Dagenais P; Urowitz MB; Gladman DD
J Rheumatol; 1994 May; 21(5):836-8. PubMed ID: 8064722
[TBL] [Abstract][Full Text] [Related]
6. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus.
Wilson K; Abeles M
J Rheumatol; 1994 Sep; 21(9):1674-7. PubMed ID: 7799348
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.
Islam MN; Hossain M; Haq SA; Alam MN; Ten Klooster PM; Rasker JJ
Int J Rheum Dis; 2012 Feb; 15(1):62-8. PubMed ID: 22324948
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T
Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate therapy in connective tissue diseases: a review of the literature.
Jeurissen ME; Boerbooms AM; van de Putte LB
Neth J Med; 1989 Aug; 35(1-2):44-58. PubMed ID: 2674740
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate therapy in childhood systemic lupus erythematosus.
Abud-Mendoza C; Sturbaum AK; Vazquez-Compean R; Gonzalez-Amaro R
J Rheumatol; 1993 Apr; 20(4):731-3. PubMed ID: 8496874
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease.
Fautrel B; Borget C; Rozenberg S; Meyer O; Le Loët X; Masson C; Koeger AC; Kahn MF; Bourgeois P
J Rheumatol; 1999 Feb; 26(2):373-8. PubMed ID: 9972972
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
14. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.
Weatherhead SC; Wahie S; Reynolds NJ; Meggitt SJ
Br J Dermatol; 2007 Feb; 156(2):346-51. PubMed ID: 17223876
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus.
Dong Y; Zhang X; Tang F; Tian X; Zhao Y; Zhang F
Chin Med J (Engl); 2001 Jul; 114(7):764-6. PubMed ID: 11780346
[TBL] [Abstract][Full Text] [Related]
17. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Fortin PR; Abrahamowicz M; Ferland D; Lacaille D; Smith CD; Zummer M;
Arthritis Rheum; 2008 Dec; 59(12):1796-804. PubMed ID: 19035431
[TBL] [Abstract][Full Text] [Related]
18. [Undifferentiated connective tissue disease: clinical and serological profile of 578 patients followed for five years: disease course, prognosis and therapy].
Bodolay E; Szegedi G
Orv Hetil; 2002 Feb; 143(5):229-33. PubMed ID: 11875835
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
